Research programme: neurodegenerative diseases diagnostics and therapeutics - AC Immune

Drug Profile

Research programme: neurodegenerative diseases diagnostics and therapeutics - AC Immune

Alternative Names: Alpha-synuclein inhibitors - AC Immune; Alpha-synuclein-PET based diagnostics and therapeutics - AC Immune; Morphomer Tau; Morphomer α-syn inhibitors - AC Immune

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Biogen
  • Class Antibodies; Antidementias; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Positron-emission tomography enhancers; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Dementia; Parkinson's disease

Most Recent Events

  • 03 Oct 2017 AC Immune plan to initiate clinical studies for the PET tracer programme in 2018
  • 22 Aug 2017 Early research in Dementia in Switzerland (unspecified route)
  • 22 Mar 2017 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top